Posts

The top performers among drugs launched in 2020 were each the first of their kind.

MiroBio and Gilead believe they can offer new, best-in-class assets to patients beset by different autoimmune diseases. The deal includes MiroBio’s lead investigational candidate, MB272, a selective agonist of T, B and dendritic cells that aims to inhibit or blunt activation and suppress an inflammatory immune response.

Weeks after announcing a significant partnership with Evotec to advance treatment for type 1 diabetes, Canada-based Sernova Corp. shared positive Phase I/II data from an ongoing clinical study of the company’s implantable Cell Pouch device that showed evidence of in vivo active insulin production following implantation of the device and islet transplantation.